2-Thiophenecarboxamide, N-(5-((4-(2-hydroxyacetyl)-1-piperazinyl)methyl)-2-((1E)-2-(1H-indazol-3-yl)ethenyl)phenyl)-3-methyl-, 4-methylbenzenesulfonate (1:1) | 1360433-93-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Thiophenecarboxamide, N-(5-((4-(2-hydroxyacetyl)-1-piperazinyl)methyl)-2-((1E)-2-(1H-indazol-3-yl)ethenyl)phenyl)-3-methyl-, 4-methylbenzenesulfonate (1:1)
• 英文别名: N-[5-[[4-(2-hydroxyacetyl)piperazin-1-yl]methyl]-2-[(E)-2-(1H-indazol-3-yl)ethenyl]phenyl]-3-methylthiophene-2-carboxamide;4-methylbenzenesulfonic acid
• CAS: 1360433-93-7
• 化学式: C35H37N5O6S2
• 分子量: 687.8
• InChiKey: SIJKXSMUXNJNQM-HRNDJLQDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.23
• 重原子数：
  48
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  193
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• METHODS FOR TREATING FIBROSIS
  申请人：Children's Hospital Medical Center

  公开号：EP3752161A1

  公开（公告）日：2020-12-23
• [EN] METHODS FOR TREATING FIBROSIS<br/>[FR] MÉTHODES DE TRAITEMENT DE LA FIBROSE
  申请人：CHILDRENS HOSPITAL MED CT

  公开号：WO2019161000A1

  公开（公告）日：2019-08-22

  Some embodiments of the invention include methods for treating an animal for fibrosis comprising one or more administrations of one or more compositions comprising one or more AURKB (Aurora kinase B) inhibitors. Other embodiments of the methods for treating further include other fibrosis treatments. Still other embodiments of the invention include methods for treating a human for lung fibrosis or idiopathic pulmonary fibrosis, comprising administering one or more compositions comprising AZD1152 or barasertib. Additional embodiments of the invention are also discussed herein.